The role of stem cell transplantation in the management of chronic lymphocytic leukaemia

被引：6

作者：

Tam, Constantine S. ^{[2
]}

Khouri, Issa ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Unit 423, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

HEMATOLOGICAL ONCOLOGY | 2009年 / 27卷 / 02期

关键词：

bone marrow transplantation; reduced intensity conditioning; rituximab; alemtuzumab; BONE-MARROW-TRANSPLANTATION; HEAVY-CHAIN GENE; NON-HODGKINS-LYMPHOMA; ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION; TREATMENT-RELATED MORTALITY; PROGRESSION-FREE SURVIVAL; MATCHED ANALYSIS; YOUNGER PATIENTS; SALVAGE THERAPY; MUTATION STATUS;

D O I：

10.1002/hon.884

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The majority of patients diagnosed with chronic lymphocytic leukaemia (CLL) will ultimately die of their disease. Stem cell transplantation (SCT) remains the only treatment modality capable of cure, but has traditionally been associated with very high morbidity and mortality. We review the results of myeloablative autologous and allogeneic SCT in CLL, discuss the evolution of the new non-myeloablative approaches, and make recommendations for when Sur should be considered in patients with CLL. Copyright (C) 2009 John Wiley & Sons, Ltd.

引用

页码：53 / 60

页数：8

共 52 条

[1] Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia [J].

Brown, Jennifer R. ;

T Kim, Haesook ;

Li, Shuli ;

Stephans, Katherine ;

Fisher, David C. ;

Cutler, Corey ;

Ho, Vincent ;

Lee, Stephanie J. ;

Milford, Edgar L. ;

Ritz, Jerome ;

Antin, Joseph H. ;

Soiffer, Robert J. ;

Gribben, John G. ;

Alyea, Edwin P. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (10) :1056-1064

[2] Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-) [J].

Caballero, D ;

García-Macro, JA ;

Martino, R ;

Mateos, V ;

Ribera, JM ;

Sarrá, J ;

León, A ;

Sanz, G ;

la Serna, JC ;

Cabrera, R ;

González, M ;

Sierra, J ;

San Miguel, J .

CLINICAL CANCER RESEARCH, 2005, 11 (21) :7757-7763

[3] INCIDENCE OF CHRONIC LYMPHOCYTIC-LEUKEMIA IN OLMSTED COUNTY, MINNESOTA, 1935 THROUGH 1989, WITH EMPHASIS ON CHANGES IN INITIAL-STAGE AT DIAGNOSIS [J].

CALL, TG ;

PHYLIKY, RL ;

NOEL, P ;

HABERMANN, TM ;

BEARD, CM ;

OFALLON, WM ;

KURLAND, LT .

MAYO CLINIC PROCEEDINGS, 1994, 69 (04) :323-328

[4] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[5] ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia [J].

Crespo, M ;

Bosch, F ;

Villamor, N ;

Bellosillo, B ;

Colomer, D ;

Rozman, M ;

Marcé, S ;

López-Guillermo, A ;

Campo, E ;

Montserrat, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18) :1764-1775

[6] Rituximab for steroid-refractory chronic graft-versus-host disease [J].

Cutler, Corey ;

Miklos, David ;

Kim, Haesook T. ;

Treister, Nathaniel ;

Woo, Sook-Bin ;

Bienfang, Don ;

Klickstein, Lloyd B. ;

Levin, Jesse ;

Miller, Katherine ;

Reynolds, Carol ;

Macdonell, Rebecca ;

Pasek, Mildred ;

Lee, Stephanie J. ;

Ho, Vincent ;

Soiffer, Robert ;

Antin, Joseph H. ;

Ritz, Jerome ;

Alyea, Edwin .

BLOOD, 2006, 108 (02) :756-762

[7] Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].

Damle, RN ;

Wasil, T ;

Fais, F ;

Ghiotto, F ;

Valetto, A ;

Allen, SL ;

Buchbinder, A ;

Budman, D ;

Dittmar, K ;

Kolitz, J ;

Lichtman, SM ;

Schulman, P ;

Vinciguerra, VP ;

Rai, KR ;

Ferrarini, M ;

Chiorazzi, N .

BLOOD, 1999, 94 (06) :1840-1847

[8] Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study [J].

Delgado, J ;

Thomson, K ;

Russell, N ;

Ewing, J ;

Stewart, W ;

Cook, G ;

Devereux, S ;

Lovell, R ;

Chopra, R ;

Marks, DI ;

Mackinnon, S ;

Milligan, DW .

BLOOD, 2006, 107 (04) :1724-1730

[9] Genomic aberrations and survival in chronic lymphocytic leukemia. [J].

Döhner, H ;

Stilgenbauer, S ;

Benner, A ;

Leupolt, E ;

Kröber, A ;

Bullinger, L ;

Döhner, K ;

Bentz, M ;

Lichter, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916

[10] Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus [J].

Dreger, P. ;

Corradini, P. ;

Kimby, E. ;

Michallet, M. ;

Milligan, D. ;

Schetelig, J. ;

Wiktor-Jedrzejczak, W. ;

Niederwieser, D. ;

Hallek, M. ;

Montserrat, E. .

LEUKEMIA, 2007, 21 (01) :12-17

← 1 2 3 4 5 6 →